Based on various press articles, it seems increasingly likely that the European Union is to abandon the earlier agreed ban on new combustion engine-based passenger cars by 2035, whilst new legislation would still require a significant reduction of tailpipe emissions. Any loosening of legislation would probably be good news for Umicore's Catalysts business, with European ICE Light duty Automotive Catalysts' revenue representing c. 28% of total ICE light duty Automotive Catalysts' revenue. We awai...
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...
Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas Ageas SA/NV (“Ageas”, the “Group”) today announced the acquisition of the outstanding 25% stake in its Belgian subsidiary AG Insurance SA/NV (“AG”) from BNP Paribas Fortis SA/NV (“BNP Paribas Fortis”). This transaction further accelerates and upgrades Ageas’s Elevate27 strategic and financial ambitions for the second time this year. Additionally, Ageas and BNP Paribas SA (“BNP Paribas”) reconfirm...
Ageas prend la pleine propriété d’AG Insurance et formalise un partenariat à long terme avec BNP Paribas Ageas prend la pleine propriété d’AG Insurance et formalise un partenariat à long terme avec BNP Paribas Ageas SA/NV (« Ageas », le « Groupe ») annonce aujourd’hui l’acquisition de la participation de 25 % du capital en circulation dans sa filiale belge AG Insurance SA/NV (« AG ») auprès de BNP Paribas Fortis SA/NV (« BNP Paribas Fortis »). Cette transaction accélère et renforce les ambitions stratégiques et financières d’Ageas dans le cadre du plan Elevate27, pour la deuxième fois cett...
Ageas wordt 100% eigenaar van AG en formaliseert lange-termijnpartnerschap met BNP Paribas Ageas wordt 100% eigenaar van AG en formaliseert lange-termijnpartnerschap met BNP Paribas Ageas SA/NV (“Ageas”, de “Groep”) kondigt vandaag de overname aan van het uitstaande belang van 25% in haar Belgische dochteronderneming AG Insurance SA/NV (“AG”) van BNP Paribas Fortis SA/NV (“BNP Paribas Fortis”). Met deze transactie versnelt en versterkt Ageas zijn strategische en financiële ambities binnen Elevate27 voor de tweede keer dit jaar. Daarnaast herbevestigen Ageas en BNP Paribas SA (“BNP Paribas”...
argenx is set for a catalyst rich year ahead and has five phase 3 trial results with its lead product, Vyvgart, as well as from the next in line product empasiprubart. Those programs are supported by positive proof of concept data, and successful phase 3 results could expand the company's commercial opportunity and bring it closer to its Vision 2030 target of having 50K patients on treatment. Going into 2026, we believe continued commercial momentum and pipeline expansion potential could bring a...
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.